Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

NOTCH2 (Notch 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

NOTCH2 mutation	Non Small Cell Lung Cancer	NOTCH2 mutation	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B	tislelizumab-jsgr Sensitive: B - Late Trials tislelizumab-jsgr Sensitive : B
NOTCH2 mutation	Non Small Cell Lung Cancer	NOTCH2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BCL6 fusion + NOTCH2 mutation	Diffuse Large B Cell Lymphoma	BCL6 fusion + NOTCH2 mutation	Diffuse Large B Cell Lymphoma	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3	rituximab Sensitive: C3 – Early Trials rituximab Sensitive : C3
NOTCH2 mutation	Diffuse Large B Cell Lymphoma	NOTCH2 mutation	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
NOTCH2-NTRK1 fusion + EGFR L858R	Lung Adenocarcinoma	NOTCH2-NTRK1 fusion + EGFR L858R	Lung Adenocarcinoma	osimertinib + larotrectinib Resistant: C4 – Case Studies osimertinib + larotrectinib Resistant : C4	osimertinib + larotrectinib Resistant: C4 – Case Studies osimertinib + larotrectinib Resistant : C4
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation	Marginal Zone Lymphoma	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	bevacizumab Resistant: C4 – Case Studies bevacizumab Resistant : C4	bevacizumab Resistant: C4 – Case Studies bevacizumab Resistant : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	nivolumab + ramucirumab Resistant: C4 – Case Studies nivolumab + ramucirumab Resistant : C4	nivolumab + ramucirumab Resistant: C4 – Case Studies nivolumab + ramucirumab Resistant : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Resistant: C4 – Case Studies carboplatin + pegylated liposomal doxorubicin Resistant : C4	carboplatin + pegylated liposomal doxorubicin Resistant: C4 – Case Studies carboplatin + pegylated liposomal doxorubicin Resistant : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	PARP inhibitor + mTORC1 inhibitor Resistant: C4 – Case Studies PARP inhibitor + mTORC1 inhibitor Resistant : C4	PARP inhibitor + mTORC1 inhibitor Resistant: C4 – Case Studies PARP inhibitor + mTORC1 inhibitor Resistant : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	carboplatin + paclitaxel Resistant: C4 – Case Studies carboplatin + paclitaxel Resistant : C4	carboplatin + paclitaxel Resistant: C4 – Case Studies carboplatin + paclitaxel Resistant : C4
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	PARP inhibitor + mTORC2 inhibitor Resistant: C4 – Case Studies PARP inhibitor + mTORC2 inhibitor Resistant : C4	PARP inhibitor + mTORC2 inhibitor Resistant: C4 – Case Studies PARP inhibitor + mTORC2 inhibitor Resistant : C4